Anti-PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC.
JCI Insight. 2022 Feb 8;7(3):e142843. doi: 10.1172/jci.insight.142843.
JCI Insight. 2022.
PMID: 35132961
Free PMC article.